18/08/2025 Izalontamab brengitecan received the Breakthrough Therapy Designation by the US FDA for EGFR-mutated NSCLC ( Ref ) The US FDA...

04/08/2025 Alphamab's IND application for JSKN022 was accepted by China's CDE ( Ref ) Alphamab Oncology's IND application for JSKN022...

24/04/2025 Ivonescimab Plus Chemotherapy Shows Statistically Significant Superiority Over Tislelizumab in First-Line Treatment of...

CAR-T therapy has dramatically changed the course of cancer management over the past few years. However, despite this impact, one of the...

Acute myeloid leukemia (AML) is the most common type of leukemia among the adult population and accounts for about 80% of all cases....

Gastric cancer has remained one of the leading causes of cancer-related deaths globally. It was reported as the 5th most common cancer...